Intellia Therapeutics (NASDAQ:NTLA) Given Buy Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report released on Friday morning,Benzinga reports. They currently have a $26.00 target price on the stock.

Several other equities analysts have also issued reports on the company. JonesTrading lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Thursday, January 22nd. HC Wainwright lifted their target price on shares of Intellia Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, January 28th. Evercore set a $8.00 price objective on shares of Intellia Therapeutics and gave the company an “in-line” rating in a research report on Tuesday, November 11th. Finally, Citizens Jmp lowered their price objective on shares of Intellia Therapeutics from $29.00 to $21.00 and set a “market outperform” rating for the company in a research note on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Intellia Therapeutics has an average rating of “Hold” and an average price target of $17.90.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA traded down $0.50 during trading hours on Friday, reaching $13.78. The company’s stock had a trading volume of 3,236,600 shares, compared to its average volume of 3,279,405. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -3.60 and a beta of 2.10. The firm has a 50-day simple moving average of $11.89 and a 200-day simple moving average of $13.02. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.16. The business had revenue of $23.02 million during the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 55.36%. The company’s revenue was up 78.4% on a year-over-year basis. During the same period in the prior year, the business posted ($1.27) earnings per share. Equities analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the sale, the executive vice president directly owned 98,533 shares of the company’s stock, valued at $907,488.93. This trade represents a 7.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP James Basta sold 10,397 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $95,756.37. Following the sale, the executive vice president directly owned 101,528 shares in the company, valued at $935,072.88. This trade represents a 9.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 53,051 shares of company stock worth $488,600. Company insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NTLA. Schroder Investment Management Group grew its stake in Intellia Therapeutics by 1,593.4% in the 2nd quarter. Schroder Investment Management Group now owns 406,425 shares of the company’s stock valued at $3,812,000 after acquiring an additional 382,425 shares during the period. Marex Group plc acquired a new position in Intellia Therapeutics during the second quarter worth $5,849,000. JPMorgan Chase & Co. lifted its holdings in Intellia Therapeutics by 73.0% during the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock valued at $8,822,000 after purchasing an additional 396,858 shares in the last quarter. AXQ Capital LP acquired a new stake in shares of Intellia Therapeutics in the second quarter valued at about $285,000. Finally, SG Americas Securities LLC grew its position in shares of Intellia Therapeutics by 239.7% in the third quarter. SG Americas Securities LLC now owns 131,070 shares of the company’s stock valued at $2,264,000 after purchasing an additional 92,485 shares during the period. 88.77% of the stock is owned by institutional investors.

More Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations: Intellia reported a smaller-than-expected loss (‑$0.83 vs. consensus ‑$0.99) and revenue of $23.0M (well above estimates), which investors view as proof of commercial progress and operational execution. Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
• Positive Sentiment: Pipeline and regulatory progress: FDA lifted the clinical hold on MAGNITUDE‑2 (nex‑z) and management outlined 2026 launch plans for lonvo‑z (HAE) with mid‑2026 Phase 3 readout expectations and a potential BLA in H2 2026 — milestones that materially de‑risk commercial timelines if achieved. Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2
• Positive Sentiment: Strong cash runway: Intellia ended 2025 with roughly $605M in cash, cash equivalents and marketable securities — a balance that supports continued clinical development and commercial preparation into the near‑term. Intellia Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” and set a $26 price target, signaling notable upside from current levels and providing dealer/retail validation for the bull case. Benzinga
• Neutral Sentiment: Broker estimates: Brookline Capital published a slate of near‑term quarterly EPS forecasts (all negative) but raised long‑range FY2028/FY2029 EPS projections, reflecting high uncertainty today but improved long‑term expectations if pipeline succeeds. MarketBeat Q4 coverage / analyst notes
• Neutral Sentiment: Earnings call detail: Management emphasized commercial readiness for lonvo‑z and clinical plans for nex‑z; transcripts and call highlights are available for deeper review. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Profitability and consensus outlook remain weak: the company still posts large negative margins and the consensus full‑year EPS forecast is deeply negative, keeping NTLA a high‑volatility, binary biotech bet until clinical/commercial milestones are met. MarketBeat: Q4 results and metrics
• Negative Sentiment: Market reaction: despite the positive operational news, the shares are trading lower today — likely reflecting profit‑taking, macro/sector pressure on biotech, and investor caution about execution risk and near‑term losses.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.